Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single-Blind Single-Ascending Dose Study of LY3971297 in HFpEF and HFrEF
jRCT2031260348Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 1, randomised, single-blind trial of LY-3971297 in heart failure (HF), heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) (12 arms), sponsored by Eli Lilly and Company. Primary endpoints: Serious adverse events related to study drug and Treatment-emergent adverse events. Started Aug 2026; status: recruiting.
02
Drugs
LY-3971297
03
Conditions
heart failure (HF)heart failure with preserved ejection fraction (HFpEF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2031260348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260348.